$2M in repeat purchase orders display Creso Pharma’s growth potential
Creso Pharma Limited (ASX:CPH, FRA: 1X8) has once again strengthened its revenue profile with another repeat purchase order from South African-based Pharma Dynamics.
Creso’s repeat purchase orders now total more than $2 million on a year-to-date basis.
This is the second purchase order from Pharma Dynamics for CPH’s cannaQIX® product – sold under the ‘Cannamics’ brand and follows the successful product launch into the South African market in March 2020.
Pharma Dynamics will distribute Creso Pharma’s hemp-based products across South Africa, with plans to extend the distribution to Namibia, Botswana, Zimbabwe, Swaziland, Lesotho, Angola, Mozambique and Uganda.
Non-Executive Chairman Mr Adam Blumenthal said of the deal, “Securing this latest purchase order with Pharma Dynamics is a significant development and highlights the multiple opportunities we are witnessing in the region. Creso Pharma is beginning to see a trend in repeat orders from its clients globally which reinforces Creso’s high quality products.”
Pharma Dynamics, a subsidiary of the $472.3BN capped Lupin Limited (NSE: LUPIN), currently ranks as the third fastest growing pharmaceutical company in South Africa, and leads the country in their supply of high-quality generics set at affordable prices.
Pharma Dynamics is well known for investments into innovative wellness programs towards holistic healthcare, with a growing range of over-the-counter products including cold and flu, allergy and immune booster products. Their products are consistently prescribed and recommended by leading doctors and pharmacists countrywide.
This successful partnership is yet another win for Creso Pharma, which as stated has received over $2M in purchase orders year-to-date.
Central to this growth has been their 100% ownership of Mernova Medical Inc. located in Nova Scotia, Canada – owner of a 24,000 square foot world-class, cannabis growing, revenue generating, Cultivation and Production Facility.
Mernova, is key to Creso Pharma’s market expansion, with part of the funds from their $8.92 million backing from institutional, professional and sophisticated investors having been earmarked for such initiatives.
Mernova Medicinal received its initial purchase order from Nova Scotia Liquor Corporation (NSLC) for the purchase of two of the group’s premium strains, HPG 13 and Lemon Haze.
The initial purchase order from Nova Scotia’s sole distributor of recreational cannabis had a value of C$180,000 (A$189,000), and the second purchase order had a value of circa $253,000. These orders from Nova Scotia display broad significance as they signalled the group’s entry into Canada’s retail markets, further diversifying Mernova’s revenue streams and adding to their growing wholesale product sales pipeline.
CPH’s growing revenue profile and international growth initiatives are further emphasised by Blumenthal: “The demand for our product on a global scale vindicates the market share initiatives we have put in place, and the recent sales in Africa and Canada shows that this strategy is not only growing the Company’s footprint but also generating significant revenue. We look forward to further capitalising on these opportunities in the near-term.”
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.